Trump's Drug Pricing Plan – What The Choice Of Words May Mean For India
Executive Summary
The Trump Administration’s blueprint on prescription drugs and reducing out-of-pocket costs may still be a work in progress, but there appears to be a careful choice of words, which some experts in developing nations like India believe are pointers on what to expect.
You may also be interested in...
Mehta Analysis: Trump Pricing Tempest In A Teapot Is An Opportunity For Biopharma Leaders
President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.
Use Of Compulsory Licensing ‘More Frequent Than Commonly Assumed’
A report in the WHO Bulletin says that the use of the TRIPS flexibilities has been much greater than is commonly assumed, dispelling the belief that such use has been sporadic and limited.
India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins
India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.